Emerging insights into thyroid cancer from immunotherapy perspective: A bibliometric analysis
Qianyu Wang Gang Pan Yu Zhang Yiqin Ni Yuzhu Mu Dingcun Luo a The Fourth School of Clinical Medicine,Zhejiang Chinese Medical University,Hangzhou First People's Hospital,Hangzhou,Zhejiang,Chinab Department of Oncological Surgery,Affiliated Hangzhou First People's Hospital,School of Medicine,Westlake University,Hangzhou,Chinac College of Mathematical Medicine,Zhejiang Normal University,Jinhua,Zhejiang,ChinaDingcun Luo,the head of the Department of Oncology Surgery and a master's supervisor at the First People's Hospital of Hangzhou,Zhejiang Province,specializes in the diagnosis and comprehensive treatment of thyroid tumors,parathyroid diseases,and breast tumors. Currently,he holds multiple positions including Deputy Secretary-General of the Thyroid Disease Branch of the Chinese Medical Promotion Association and Head of the Neck Lymph Node Dissection Study Group; Deputy Director of the Head and Neck Professional Committee of the National Minimally Invasive Oncology Alliance; Executive Committee Member of the Clinical Practical Technology Branch of the China International Health Care Exchange Promotion Association; Committee Member of the Thyroid Disease Professional Committee of the Chinese Preventive Medicine Association; Committee Member of the Thyroid Cancer Professional Committee of the China Anti-Cancer Association; Deputy Director of the Oncology Surgery Branch of the Zhejiang Medical Association; and Vice President of the Oncology Surgery Branch of the Zhejiang Physician Association,among others. He has undertaken or participated in over 10 national and provincial-level projects,published over 80 papers in SCI and Chinese journals,contributed to 8 expert consensus and guidelines,holds 8 patents,and has received 11 awards including the Zhejiang Science and Technology Progress Award.
DOI: https://doi.org/10.1080/21645515.2024.2403170
2024-09-19
Human Vaccines & Immunotherapeutics
Abstract:Thyroid cancer is a common endocrine malignancy that poses considerable therapeutic challenges in treating anaplastic carcinoma and advanced aggressive disease. Immunotherapy has become a prominent strategy for cancer treatment, and has shown remarkable advancements in recent years. In this study, we utilized visualization and bibliometric tools to analyze publications on thyroid cancer immunotherapy from the Web of Science Core Collection (WoSCC). A total of 409 articles were included, with an annual increase in both publications and citations since 2016. China leads research efforts in this area, while the University of Texas System and UTMD Anderson Cancer Center rank first in publication output. The journal Thyroid has garnered the highest citations. Notable authors contributing to this field include Antonelli Alessandro, Fallahi Poupak, and Wang Yu. Current research hotspots include immune checkpoint inhibitors, combination therapies involving immunotherapy with targeted therapy, CAR-T cell therapy, and modulation of the tumor microenvironment, all of which underscore the evolving landscape and potential for innovative treatments in thyroid cancer.
immunology,biotechnology & applied microbiology